Advanced Imaging


Industry News

Updated: July 8th, 2008 05:26 PM CDT

Clarient Sells Its ACIS Instrument Business to Carl Zeiss for $12.5 Million

via PRNewswire

About Carl Zeiss MicroImaging GmbH

Carl Zeiss MicroImaging GmbH offers microscopy solutions and systems for research, laboratories, routine and industrial applications, as well as spectral sensors for the analysis market. The company develops, produces and markets instruments, software and accessories for microscope systems and associated techniques. Microscopy from Carl Zeiss is present in all major future-oriented markets. The spectrum of products ranges from traditional light and stereo microscopes to laser scanning systems and automated microscope systems, covering applications ranging from biotechnology, pharmaceutical research, health care and biomedicine to quality assurance and materials analysis. It is supplemented by an extensive line of single components such as gratings, spectral sensors, spectrometer units and specific solutions in process analysis.

Carl Zeiss MicroImaging GmbH emerged from the Microscopy Group as a 100% subsidiary of Carl Zeiss AG on March 01, 2006 . During fiscal year 2005/06, the Microscopy Group at Carl Zeiss generated revenues of approximately EUR 340 million (USD 440 million) with a global workforce of about 1600. For more information on Carl Zeiss MicroImaging GmbH please visit

About Safeguard

Safeguard Scientifics, Inc. (NYSE: SFE) builds value in growth-stage technology and life sciences businesses. Safeguard provides growth capital as well as a range of strategic, operating and management resources to our partner companies. The company participates in expansion financings, corporate spin-outs, management buyouts, recapitalizations, industry consolidations and early-stage financings. For more information,

About Susquehanna International Group, LLP

Susquehanna International Group, LLP is the parent company to The Susquehanna International Group of companies (SIG). Headquartered in BalaCynwyd, Pennsylvania, SIG is a leading financial institution focusing on trading and market making, investment banking, institutional sales and research, private equity and venture capital. SIG makes markets in more than 10,000 financial products, including equities, fixed income, energy, currencies and commodities. SIG is among the nation's largest option market makers, is the leading sector index options trading firm and is one of the largest liquidity providers in ETFs. To drive its continued growth, SIG leverages its highly dynamic, internally developed quantitative trading tools and technology to assist in its market making operations. SIG's global reach spans more than 12 offices across North America , Europe and Asia. For more information, please visit

The statements herein regarding Clarient, Inc. contain forward-looking statements that involve risks and uncertainty. Future events and the Company's actual results could differ materially from the results reflected in these forward-looking statements. Factors that might cause such a difference include, but are not limited to: the Company's ability to continue to develop and expand its services group business, the Company's ability to expand and maintain a successful sales and marketing organization, the continuation of favorable third party payer reimbursement for laboratory tests, the Company's ability to obtain additional financing on acceptable terms or at all, the Company's ability to agree upon new financial covenants with GE Capital and to extend or obtain waivers of certain defaults under its credit facilities, the Company's ability to successfully complete a joint development agreement with Zeiss for the development of novel markers, whether the conditions to payment of all or any portion of the contingent consideration from the transaction are satisfied, unanticipated expenses or liabilities or other adverse events affecting cash flow, uncertainty of success in identifying and developing new diagnostic tests or novel markers, failure to obtain FDA clearance or approval for particular applications, the Company's ability to compete with other technologies and with emerging competitors in novel cancer diagnostics and dependence on third parties for collaboration in developing new tests, and risks detailed from time to time in the Company's SEC reports, including quarterly reports on Form 10-Q, reports on Form 8-K and annual reports on Form 10-K. Recent experience with respect to laboratory services, revenues and results of operations may not be indicative of future results for the reasons set forth above.

Subscribe to our RSS Feeds